Human Immunology News

Human Immunology News is an online publication and email newsletter for researchers studying the human immune system.

Low-Dose IL-2 Reduces IL-21+ T Cell Frequency and Induces Anti-inflammatory Gene Expression in Type 1 Diabetes

[Nature Communications] Researchers examined the effects of interval administration of low-dose recombinant IL-2 in type 1 diabetes using high-resolution single-cell multiomics and flow cytometry on longitudinally-collected peripheral blood samples.

Identification of Common and Distinct Origins of Human Serum and Breastmilk IgA1 by Mass Spectrometry-Based Clonal Profiling

[Cellular & Molecular Immunology] Researchers assessed the structural diversity and clonal repertoire of IgA1-containing molecular assemblies longitudinally in human serum and milk from three donors using a mass spectrometry-based approach.

Tim-4 Reprograms Cholesterol Metabolism to Suppress Antiviral Innate Immunity by Disturbing the Insig1-SCAP Interaction in Macrophages

[Cell Reports] Mechanistically, T cell immunoglobulin and mucin domain-containing molecule 4 (Tim-4) disturbed the Insig1-SCAP interaction and promoted SCAP-SREBP2 complex translocation to the Golgi apparatus.

Early Microbial Exposure Shapes Adult Immunity by Altering CD8+ T Cell Development

[Proceedings of the National Academy of Sciences of the United States of America] Early microbial exposure resulted in the preferential expansion of highly responsive fetal-derived CD8+ T cells that persist into adulthood and provide the host with enhanced immune protection against intracellular pathogens.

Phosphofructokinase P Fine-Tunes T Regulatory Cell Metabolism, Function, and Stability in Systemic Autoimmunity

[Science Advances] In Treg cells, a CRISPR-Cas9–enabled Pfkp deletion recapitulated the metabolism of Camk4−/− Treg cells, and improved their function and stability in vitro and in vivo.

Identification of Biomarkers to Stratify Response to B-Cell-Targeted Therapies in Systemic Lupus Erythematosus: An Exploratory Analysis of a Randomised Controlled Trial

[Lancet Rheumatology] The authors found a predictive association between baseline serum IgA2 anti-double stranded DNA antibody concentrations and clinical response to belimumab after rituximab, with a between-group difference in major clinical response of 48% (95% CI 10 to 70).

Gene Therapy for Inborn Errors of Immunity: Past, Present and Future

[Nature Reviews Immunology] The author summarizes the journey of the past 25 years that has led to the successful use of gene therapy for Inborn errors of immunity and discusses the next steps for the field.

BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates

[BioNTech and Ryvu Therapeutics] The two companies have entered into a multi-target research collaboration for several small molecule immunotherapy programs as well as an exclusive license agreement for Ryvu’s STING agonist portfolio as standalone small molecules.

Lupus Foundation of America Announces Recipients of the Gary S. Gilkeson Career Development Award

[Lupus Foundation of America] The Gary S. Gilkeson Career Development Award was designed for fellows and clinicians with the goal of supporting early career scientists and providing mentorship during a critical time in their lupus research career.

Neuroimmune Transcriptome Changes in Patient Brains of Psychiatric and Neurological Disorders

[Molecular Psychiatry] 1275 immune-related genes were curated and their expression changes investigated in 2467 postmortem brains of controls and patients with six major brain disorders, including schizophrenia, bipolar disorder, autism spectrum disorder, major depressive disorder, Alzheimer’s disease, and Parkinson’s disease.

Dr. Michael Nathanson Receives AASLD Distinguished Service Award

[Yale School of Medicine] Michael Nathanson, MD, PhD, Gladys Crofoot Professor of Medicine (Digestive Diseases) and professor of cell biology, received the 2022 Distinguished Service Award from the American Association for the Study of Liver Disease (AASLD) during its annual meeting.

CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naïve/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

[Cancer Discovery] Ten patients were treated with 36–165 x 106 CART19/20 cells. No patient experienced neurotoxicity of any grade, or over grade-1 cytokine release syndrome. One case of dose-limiting toxicity was observed.

Each issue of Human Immunology News provides up-to-date coverage of the latest news in immunology research performed using human cells or subjects. Our expert editors hand-pick recent research papers and review articles from relevant high-impact peer-reviewed journals on topics including immunotherapy, autoimmunity, adaptive, and innate immunity in humans. We also feature news on clinical trials, award announcements, and funding opportunities.

spot_img